Use for 1,3-propanediol derivatives
AssigneeNovartis AG
InventorsSylvain Cottens, Robert Paul Hof, Roland Wenger
Life of this patent
Estimating the term…
Abstract
Use of a compound of formula I wherein R1 is an optionally substituted straight- or branched carbon chain having 12 to 22 carbon atoms which may be optionally interrupted by an optionally substituted phenylene, and each of R2, R3, R4 and R5, independently, is H or lower alkyl, in free form or in pharmaceutically acceptable salt form, in the prevention or treatment of chronic rejection in a recipient of organ or tissue allo- or xenotransplant, or of acute rejection in a xenograft transplant recipient.
Claims25
A method of preventing or treating chronic rejection in a patient receiving an organ or tissue allo-transplant comprising administering to the patient an effective amount of 2-amino-2-[2-(4-octylphenyl)ethyl]-1,3-propanediol or its pharmaceutically acceptable salt with an effective amount of a second immunomodulatory or anti-inflammatory agent selected from the group consisting of a cyclosporin, a rapamycin, an ascomycin, a corticosteroid, cyclophosphamide, azathioprene, methotrexate, bequinar, leflunomide, mizoribine, 15-deoxyspergualine, immunosupressive monoclonal antibodies, and CTLA4-lg.
Dependencies are inferred from the claim text.